‘Viead’ cruises both in prescription and import
While ‘Viread(generic name: tenofovir), the Gilead’s hepatitis B therapy, outnumbered BMS’s ‘Baraclude’ and became the top in the ETC drug market, it continued a smooth flow as recording a significant growth in the import amount.
Based on the ‘2015 Pharmaceutical Manufacturing Performance’ recen...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
